Cerus Q3 2026 Earnings: Product Revenue Rises 10% as Gross Margin Narrows

Cerus (Nasdaq: CERS) reported Q3 2026 total revenue of $64.0 million, up 6% year over year, while GAAP diluted loss per share remained $0.00 on a rounded basis. Product revenue grew 10% to $57.7 million, but a lower product gross margin and higher SG&A contributed to a wider attributable net loss of $0.6 million. Operating cash flow improved to $3.0 million, and Cerus announced positive topline Phase 3 RedeS results for its INTERCEPT red blood cell system.

Core Financial Results

Product revenue growth was the main driver of the quarter, supported by higher U.S. INTERCEPT Fibrinogen Complex sales, the U.S. platelet franchise, and INT200 illuminator sales in Europe, the Middle East, and Africa. Government contract revenue fell 16% to $6.3 million following the completion of an FDA contract and the wind-down of Cerus’ 2016 BARDA contract, partly offset by activity under its 2024 BARDA contract.

Product gross profit rose more slowly than product revenue as the related margin declined by 100 basis points. Non-GAAP adjusted EBITDA and operating cash flow increased, but GAAP operating income fell and the net loss widened.

Adjusted EBITDA excludes items including government contract revenue and related direct expenses, share-based compensation, depreciation and amortization, and non-operating expenses. It therefore is not directly comparable with GAAP operating income.

Business and Regional Performance

North America generated most of the product revenue increase. U.S. IFC sales rose to $5.6 million from $3.9 million, an increase of approximately 44%, while total IFC demand measured in FC15-equivalent units increased approximately 80%. Cerus also cited strength in its core U.S. platelet franchise.

EMEA product revenue increased 5%, helped by INT200 illuminator sales. However, international platelet kit sales declined 3%, compared with 5% growth in North America. Worldwide platelet kit growth was 3%, while the calculated number of treatable platelet doses increased 2%.

Cerus separately announced positive topline results from the Phase 3 RedeS trial of the INTERCEPT Blood System for red blood cells. The release did not provide numerical endpoint results or a detailed analysis, leaving the complete study findings and subsequent regulatory steps as future milestones.

Product Growth Did Not Flow Through to Higher GAAP Profit

The 10% increase in product revenue produced only 8% growth in product gross profit because product gross margin declined from 53.4% to 52.4%. Cerus attributed the reduction mainly to a weaker U.S. dollar against the euro and inflation-driven product costs. Pricing and a more favorable product mix provided partial offsets.

Total operating expenses increased 5% to $36.2 million. R&D expense fell approximately 10% to $14.3 million as enrollment in the RedeS study was completed, INT200 development progressed beyond the U.S. premarket approval submission, and government-funded project expenses declined.

SG&A moved in the opposite direction, increasing approximately 18% to $21.9 million. Cerus cited higher employee-related costs, while the prior-year quarter had also benefited from a one-time tax credit. Together with lower government contract revenue and margin pressure, this reduced GAAP operating income to $0.383 million. Although non-operating expense improved from the prior year, it was still sufficient to produce a $0.550 million attributable net loss.

Cash Flow and Balance Sheet

Operating cash flow increased to $3.0 million from $1.9 million. Cerus attributed the improvement to sequentially better bottom-line results and inventory management.

Cash, cash equivalents, and short-term investments reached $57.1 million at September 30, 2026, up $0.8 million from June 30 but down from $82.9 million at the end of 2025. The company had $35.0 million outstanding on its term loan and $28.5 million drawn under its revolving credit facility. Another $16.5 million was available under the revolver, subject to borrowing-base levels.

Full-Year Guidance

Cerus reiterated its full-year 2026 product revenue outlook, leaving both the overall product revenue and IFC ranges unchanged. The maintained outlook calls for product revenue growth of 11% to 12% from 2025.

Recent Insider Transactions

The supplied six-month aggregate reported 1,058,129 shares under purchases across eight transactions and 302,737 shares sold across nine transactions, resulting in net purchases of 755,392 shares. Total insider holdings were listed at approximately 7.28 million shares, with net purchases equal to 11.6% of that amount.

The 10 latest individual entries covered a different subset of records: seven sales with a combined reported value of approximately $790,672 and three stock awards reported at zero value. No purchase entry appeared among these 10 transactions, and the transactions alone do not establish insiders’ views on Cerus’ prospects.

Roles in the table are presented as shown in the supplied transaction data.

Risks Investors Need to Watch

• Product margin pressure: Foreign-exchange movements and inflationary product costs reduced product gross margin by 100 basis points. Continued pressure could limit the profit contribution from higher product sales.
• Lower government contract revenue: Contract completion and wind-down activity reduced government contract revenue by 16%, causing total revenue to grow more slowly than product revenue.
• Commercial execution: The full-year outlook depends on continued IFC adoption, U.S. platelet growth, and the INT200 rollout. International platelet kit sales declined during the quarter despite higher overall EMEA product revenue.
• Liquidity and debt: Cash and short-term investments remained above the June level but were below the year-end balance. Cerus also had $63.5 million outstanding across its term loan and revolver, while additional borrowing capacity remains subject to the borrowing base.
• Clinical and regulatory uncertainty: RedeS produced positive topline results, but the complete analysis was not included. The INTERCEPT red blood cell system and INT200 remain subject to regulatory review and approval processes.

Conclusion

Cerus’ Q3 2026 results showed continued product revenue growth led by IFC, U.S. platelets, and INT200 sales, alongside improved operating cash generation. That growth did not translate into higher GAAP profit because product margin narrowed, SG&A increased, and government contract revenue declined. The principal items to monitor are execution against the reiterated product revenue guidance, stabilization of product gross margin, the sustainability of positive operating cash flow, and the next clinical and regulatory steps for the red blood cell system.